Value
6.3/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 6.7 |
| Fwd P/E | 1.0 |
| PEG | 9.8 |
| Analyst target | 7.5 |
- ▸Forward P/E: 120.3x
- ▸PEG: 0.54
IRTC · Why this verdict
Why iRhythm Holdings (IRTC) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company has delivered four consecutive earnings beats with an average quarterly surprise exceeding 140%, a pattern of consistently and materially outperforming market expectations that signals disciplined execution against its own guidance. Catalyst breakdown | The beat streak extends to at least five consecutive quarters with each quarterly surprise remaining positive. | →Stable |
| CounterThe outsized surprise percentages partly reflect very low or negative estimate bases, where missing by a small amount in absolute dollars registers as a large positive percentage surprise — if estimates reprice meaningfully upward to track the pattern of outperformance, future beats will be structurally harder to achieve. | ||
Revenue is expanding at 26% year-over-year, with the company ranking as an industry growth leader among peers, and the PEG ratio of 0.48 suggests the market has not yet fully valued the earnings trajectory implied by that growth rate. Growth breakdown | Revenue growth rate stays above 20% year-over-year for two consecutive quarters. | →Stable |
| CounterConcentrated revenue from a single service offering means that any reimbursement disruption, competitive entry, or regulatory constraint on that product could sharply curtail the growth rate — and a 26% figure from a single-product company carries more execution risk than equivalent growth from a diversified portfolio. | ||
A critical event filing and outstanding legal proceedings have blocked a clean technical setup, creating headline risk that could compress the stock before the underlying growth thesis plays out. Engine gate (failed) | Legal proceedings resolve without material financial settlement and no new related critical filings emerge over the next six months. | →Stable |
| CounterCritical event filings and legal matters are common among growth-phase medical device companies; if the exposure proves immaterial or settles at a modest amount, the overhang lifts and the growth re-rating can begin quickly from current levels. | ||
The stock is trading below its 200-day moving average, which is declining at 3.7% per month — a confirmed downtrend that typically requires a catalyst-driven re-rating to reverse rather than a gradual technical recovery. Momentum breakdown | Price recovers above the 200-day moving average and the moving average slope turns flat or positive within 12 months. | →Stable |
| CounterImproving MACD and rising volume accumulation suggest buying pressure is building beneath the surface; if the next earnings release is large enough to shift sentiment, the technical downtrend can reverse quickly from an oversold base without needing the 200-day average to first flatten. | ||
The company has delivered four consecutive earnings beats with an average quarterly surprise exceeding 140%, a pattern of consistently and materially outperforming market expectations that signals disciplined execution against its own guidance.
→StableCatalyst breakdown
- Expectation
- The beat streak extends to at least five consecutive quarters with each quarterly surprise remaining positive.
CounterThe outsized surprise percentages partly reflect very low or negative estimate bases, where missing by a small amount in absolute dollars registers as a large positive percentage surprise — if estimates reprice meaningfully upward to track the pattern of outperformance, future beats will be structurally harder to achieve.
Revenue is expanding at 26% year-over-year, with the company ranking as an industry growth leader among peers, and the PEG ratio of 0.48 suggests the market has not yet fully valued the earnings trajectory implied by that growth rate.
→StableGrowth breakdown
- Expectation
- Revenue growth rate stays above 20% year-over-year for two consecutive quarters.
CounterConcentrated revenue from a single service offering means that any reimbursement disruption, competitive entry, or regulatory constraint on that product could sharply curtail the growth rate — and a 26% figure from a single-product company carries more execution risk than equivalent growth from a diversified portfolio.
A critical event filing and outstanding legal proceedings have blocked a clean technical setup, creating headline risk that could compress the stock before the underlying growth thesis plays out.
→StableEngine gate (failed)
- Expectation
- Legal proceedings resolve without material financial settlement and no new related critical filings emerge over the next six months.
CounterCritical event filings and legal matters are common among growth-phase medical device companies; if the exposure proves immaterial or settles at a modest amount, the overhang lifts and the growth re-rating can begin quickly from current levels.
The stock is trading below its 200-day moving average, which is declining at 3.7% per month — a confirmed downtrend that typically requires a catalyst-driven re-rating to reverse rather than a gradual technical recovery.
→StableMomentum breakdown
- Expectation
- Price recovers above the 200-day moving average and the moving average slope turns flat or positive within 12 months.
CounterImproving MACD and rising volume accumulation suggest buying pressure is building beneath the surface; if the next earnings release is large enough to shift sentiment, the technical downtrend can reverse quickly from an oversold base without needing the 200-day average to first flatten.
TrendMatrix Research · core thesis
Engine thesis — one sentence
iRhythm has posted four straight earnings beats with average quarterly outperformance exceeding 140%, is growing revenue at 26% year-over-year, and carries analyst-implied upside of roughly 37% — but a confirmed price downtrend, a pending legal proceeding, and a critical event disclosure currently block a clean setup and warrant a watchful posture rather than an immediate position.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.8 |
| FCF quality | 4.4 |
| Moat | 5.8 |
| Rule of 40 | 5.5 |
| Piotroski F | 6.7 |
- ▸FCF-positive despite GAAP loss (FCF margin 7%, FCF yield 1.4%)
Growth
9.4/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 8.9 |
| EPS growth | 10.0 |
- ▸Strong growth: 26% YoY
Momentum
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.2 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 2.7 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -5.4%/30d — confirmed downtrend
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.6 |
| Price target | 9.2 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 41%
Insider
4.1/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.7 |
| holder change | 5.1 |
- ▸Modest insider selling — $956,552 (0.023% of mkt cap)
Peer rank
3.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.7 |
| quality rank | 3.2 |
| growth rank | 7.7 |
Technical
0.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.7 |
| 52w position | 1.9 |
Risk (lower is worse)
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.5 |
| days to cover | 4.9 |
| volatility | 1.2 |
| put call | 10.0 |
| implied vol | 2.4 |
| beta | 5.9 |
| debt equity | 0.5 |
- ▸High IV: 65%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:6.4>=5.5
- ASYMMETRY:1.5>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:27d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- 8K_CRITICAL:4.01
Warning (1)
- DEATH_CROSS:momentum=6.4>=5.0 recovering
Reward-to-Risk
1.54
Upside
+23.1%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 68
EdgeCatalyst-Driven — Earnings in 27d with 4/4 beat streak
SuitabilitySpeculative — Drawdown -40% (>40% off 52w high)
Investment implication
The F-path SELL output reflects an overall score of 4.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 9.4) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( 8K_CRITICAL:4.01) reinforce the read. Current asymmetry R:R is 1.54 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 9.4, Sentiment at 7.8, and Catalyst at 7.5; the weakest are Technical at 0.9, Peer rank at 3.4, and Quality at 4.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 1.54 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perfect Earnings Beat Streak
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Strong Revenue Growth Trajectory
Trip ifRevenue growth falls below 15% YoY for 2 consecutive quarters.
- P3Critical Events Legal Risk Overhang
Trip ifLegal matter resolves or is dismissed with financial impact below $25 million and no new critical 8-K events filed in the following 6 months.
- P4Confirmed Downtrend Below 200 Ma
Trip ifPrice rises above the 200-day moving average and holds above it for at least 15 consecutive trading sessions.